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Para os meus pais e avós, 
os meus primeiros mentores 
“If I have seen further it is by standing on the shoulders of Giants.” 
Isaac Newton 
ABSTRACT 
Our understanding of cancer biology has been evolving rapidly shaped by groundbreaking 
discoveries. We now understand that cancer is not one disease but many, and that tumors are 
not foreign objects in the human body but rather the result of changes in the previously normal 
tissues and organs. Thus, in order to ask fundamental questions and dissect the complexity of 
cancer it is essential to grasp how the healthy organs develop and function and the cellular and 
molecular mechanisms involved. The serine/threonine PAKs are signaling hubs with proven 
roles in development and disease. Specifically, they are important to several hallmarks of 
cancer. Thus, the family in general, and PAK4 in particular, is increasingly attracting the 
interest of the scientific community.  
In this thesis I have explored the role of PAK4 in normal organ development and cancer. Novel 
mouse models with PAK4 depletion in the mammary gland and in the pancreas have been 
established and characterized in Paper I and Paper II. The absence of major tissue 
abnormalities upon PAK4 depletion in the mammary epithelium allowed me to use this model 
to study the role of PAK4 in tumorigenesis in vivo, in Paper III, and a counterpart mouse 
model with PAK4 overexpression in the mammary epithelium was also generated. These 
complementary in vivo setups showed that PAK4-overexpressing mammary glands 
occasionally developed mammary tumors while PAK4 abrogation impaired PyMT-driven 
mammary tumorigenesis. Extensive in vitro experiments, using state of the art techniques, then 
supported a model in which PAK4 confers selective advantages to cancer cells by overcoming 
the senescence barrier. This, in turn, constitutes a selective vulnerability of cancer cells that 
become susceptible to a senescence-like response upon PAK4 inhibition. The data presented 
also demonstrates a crosstalk between PAK4 and NF-κB signaling, and a direct interaction and 
phosphorylation site within the REL-homology domain of RELB is found to be relevant for 
tuning RELB-mediated transcription and cancer cell proliferation via C/EBPβ. Importantly, 
these findings were largely supported by correlations in clinical data and validated ex vivo in 
patient-derived cells, thus highlighting PAK4 as an attractive therapeutic opportunity in cancer. 
Therefore, this thesis contributes to a better understanding of the mechanisms that govern breast 
tumorigenesis, with hopes that such knowledge will prove relevant in cancer prognosis and 
treatment. 
  
RESUMO 
O entendimento da biologia do cancro tem vindo a progredir rapidamente, esculpido por 
descobertas inovadoras. Atualmente entendemos que cancro não é uma única doença, mas sim 
uma multiplicidade de patologias, e que os tumores não são objetos estranhos no corpo 
humano, mas antes o resultado de alterações nos tecidos e órgãos outrora normais. Assim, para 
fazer face a questões fundamentais e dissecar a complexidade que o cancro apresenta, é 
essencial compreender o normal desenvolvimento e funcionamento dos órgãos e os 
mecanismos celulares e moleculares envolvidos. As serina/treonina cinases PAK ocupam um 
lugar central em cascatas de sinalização e têm importância demonstrada tanto no normal 
desenvolvimento como em situações patológicas. Especificamente, as PAKs são relevantes em 
várias vertentes do cancro. Por isso, o interesse da comunidade científica sobre esta família em 
geral, e sobre PAK4 em particular, tem vindo a aumentar. 
Nesta tese, explorei o papel da PAK4 no desenvolvimento normal dos órgãos e em cancro. 
Modelos animais (ratinhos), previamente inexistentes, com deleção da PAK4 na glândula 
mamária e no pâncreas foram criados e caracterizados no Artigo I e no Artigo II. A ausência 
de anomalias no epitélio mamário após a deleção da PAK4 permitiu o uso deste modelo na 
investigação das funções que a PAK4 desempenha no processo de tumorigénese in vivo, no 
Artigo III, onde também foi gerado um modelo reverso: um ratinho com sobrexpressão da 
PAK4 no epitélio mamário. Essas estratégias complementares in vivo revelaram que as 
glândulas mamárias com sobrexpressão da PAK4 ocasionalmente desenvolviam tumores 
mamários, enquanto que a deleção da PAK4 atrasava o processo de tumorigénese mamária 
induzida pelo oncogene PyMT. Experiências in vitro usando tecnologia de ponta apoiaram um 
modelo no qual a PAK4 confere vantagens seletivas às células cancerígenas, transpondo a 
barreira anti-tumoral incutida pelo processo de senescência. Isso, por sua vez, constitui uma 
vulnerabilidade seletiva das células cancerígenas que se tornam suscetíveis a senescência 
perante inibição da PAK4. Os resultados apresentados também demonstram uma interligação 
entre a sinalização celular da PAK4 e do NF-κB e identificam uma interação e fosforilação no 
domínio de ligação ao DNA (domínio de homologia REL) do fator de transcrição RELB, que 
se revelou relevante para a regulação da transcrição mediada por RELB e para a proliferação 
de células cancerígenas via C/EBPβ. É importante salientar que estes resultados experimentais 
foram amplamente sustentados por correlações em dados clínicos humanos e validados ex vivo 
em células derivadas de pacientes com cancro de mama, destacando a proteína PAK4 como 
um potencial alvo terapêutico para o cancro. 
Esta tese contribui assim para uma melhor compreensão dos mecanismos que governam o 
processo de tumorigénese das neoplasias da mama, na esperança de que este conhecimento se 
venha a relevar relevante no prognóstico e tratamento destas patologias. 
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1 INTRODUCTION 
1.1 CELLS, TISSUES AND ORGANS 
The human body contains over 1013 cells (Bianconi et al., 2013) that can all be traced back to 
the fertilized egg (Xavier da Silveira Dos Santos and Liberali, 2019). During development, 
discrete populations of stem cells undergo progressive differentiation and, through multiple 
repeated cycles of cell division, various cell types ultimately organize into functional tissues 
and organs (Bryant and Mostov, 2008). As such, cells have been postulated as the “building 
blocks of life”, that is, the basic unit of structure and function of living organisms (Schwann et 
al., 1847).  
Cells integrate intricate chemical and mechanical, intracellular and extracellular, local and 
systemic cues, and they reciprocally interact with each other and their environment (Bryant and 
Mostov, 2008; Xavier da Silveira Dos Santos and Liberali, 2019). This highly regulated 
behavior in space and time is critical to tissue homeostasis and function (Mayr et al., 2019).  
1.2 THE MAMMARY GLAND 
1.2.1 The anatomy and physiology of the mammary gland 
The mammary gland is an exceptional secretory organ that gave an entire class of animals its 
name, mammals (Peaker, 2002). Its primary function is lactation, the synthesis and secretion 
of nutritional and protective milk from the mother to the young, credited as essential for the 
evolutionary success of mammals (Peaker, 2002). 
The number and positioning of mammary glands vary among mammals (Veltmaat et al., 2013) 
but they are frequently present in pairs (i.e. 2 pairs in most primates but up to 7-10 pairs in 
pigs) (Rezaei et al., 2016; Veltmaat et al., 2013). Only rarely are mammary glands present in 
odd number (i.e. in some opossums) (Krause et al., 2006). Male mammals usually have 
rudimentary mammary glands and nipples with the exception of male mice that lack nipples 
(Cardiff and Allison, 2012) and the male Dayak fruit bat that has lactating mammary glands 
(Francis et al., 1994). The human females have two mammary glands that are enclosed within 
the breasts [Figure 1] while female rodents, specifically mice, have 10 mammary glands that 
are encased within mammary fat pads (Cardiff and Allison, 2012) [Figure 2]. Importantly, the 
organization of the murine mammary gland is fundamentally similar to the human counterpart, 
and the mouse is therefore a useful model to study mammary gland biology in health and 
disease (Cardiff and Allison, 2012).  
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The mammary gland is an elaborate network of continuously branched ducts that extends 
radially from the nipple, in an architecture that maximizes the surface area within a constrained 
volume and is thus common in organs whose function is to transport fluid (Gjorevski and 
Nelson, 2011) [Figure 1]. The two-layered mammary epithelial ductal tree is encased by a 
collagen-rich basement membrane and surrounded by a stroma containing adipocytes, 
fibroblasts, blood and lymph vessels, nerves and various immune cells (Pellacani et al., 2019) 
[Figure 1]. Historically the stroma has been regarded as a single compartment but recent 
studies are dissecting and revealing distinct and important roles played by each of these cell 
populations and the overall microenvironment in normal mammary gland development and 
function (Polyak and Kalluri, 2010).  
Figure 1 | Regional anatomy, macro- and microscopic structure of the adult human breast. . 
(A) Schematic diagrams of the mammary gland of an adult human female, located over the pectoralis major muscle
of the chest. Mammary gland pyramidal lobules (also named TDLUs) are embedded in fibrous and adipose tissue
and connect to a ductal system that extends radially from the nipple.                                                                                                    .
(B) Histological sections of a duct and a lobule (a cluster of alveoli) and schematic diagram of a mammary alveolus
highlighting its assorted basic components. Scale bar 100 micrometers.
Panel A: “Breast Anatomy Female”: For the National Cancer Institute © 2011 Terese Winslow LLC, U.S. Govt. has certain rights. . 
Panel B: From Pellacani et al., 2019 
Epithelial cells 
The mammary epithelial ductal tree comprises one internal layer of luminal epithelial cells 
around an empty lumen and an outer layer of myoepithelial cells (also known as basal layer) 
in direct contact with the basement membrane (Pellacani et al., 2019). The luminal epithelial 
cells that line the ducts are apically oriented, express keratins 8 and 18 and differentiate into 
milk-producing alveoli upon hormonal induction (Inman et al., 2015). The basal myoepithelial 
cells express keratins 5 and 14 and α-SMA that mediates its contractile, smooth muscle-like 
properties, thereby facilitating the release of milk upon hormone-triggered contraction (Forsyth 
and Neville, 2009). Additionally, and consistent with the cyclic mammary gland remodeling 
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occurring over the lifetime of a female, several putative mammary stem and progenitor cell 
populations have been identified by cell-sorting experiments (Shackleton et al., 2006; Stingl et 
al., 2006; Visvader and Stingl, 2014).  
Adipocytes 
Fat-filled adipocytes are the largest population of cells within the mammary fat pad (Bartley et 
al., 1981). Their role in mammary gland function has been largely overlooked, but recent 
studies indicate that adipocytes express several key ligands and receptors and are thereby 
thought to regulate epithelial growth, function and angiogenesis (Hovey and Aimo, 2010). 
Importantly, adipocytes with reduced lipid content are observed during pregnancy and 
lactation, suggesting that milk production is a metabolically demanding process that may 
benefit from this fat reservoir (Gregor et al., 2013). 
Fibroblasts 
The mammary fibroblasts are found either embedded within the fat pad or in close proximity 
to the basal myoepithelium (Muschler and Streuli, 2010). Depending on their location, within 
fatty or collagenous environments, they display substantial differences in protein expression 
and are thus a heterogeneous cell population (Fleming et al., 2008). Fibroblasts affect 
mammary branching morphogenesis through direct synthesizes and secretion of a number of 
growth factors, ECM components and various MMPs (Simian et al., 2001; Wiseman and Werb, 
2002). MMPs degrade the ECM and concomitantly facilitate the release of growth factors and 
cytokines (Simian et al., 2001; Wiseman and Werb, 2002). Fibroblasts can thereby regulate 
epithelial cell features and phenotype by altering the composition, density and stiffness of the 
ECM (Luhr et al., 2012). 
Blood and lymph 
The lymphatic network and the blood vasculature develop in close association with the 
mammary epithelial tree during puberty (Betterman et al., 2012). Both vascular and lymphatic 
networks are vital during lactation for carrying nutrients and fluids into milk (Gjorevski and 
Nelson, 2011).  
Immune cells 
Various cells of the immune system can be found within the mammary gland stroma (Reed and 
Schwertfeger, 2010). Macrophages, eosinophils and mast cells have all been shown to regulate 
branching morphogenesis, in part, by altering the production of ECM and/or its organization 
near the growing epithelial ducts (Atabai et al., 2007). 
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1.2.2 Mammary gland development 
The mammary gland changes dramatically as it develops and it maintains a remarkable capacity 
to undergo continuous phases of remodeling and regeneration during adulthood (Cardiff and 
Allison, 2012). Throughout all these stages, cells of the mammary gland proliferate, 
differentiate or die, altering the glands architecture to fulfill its function (Inman et al., 2015). 
In humans and mice alike, the development of the mammary gland can be split into embryonic, 
pubertal and adult stages, with the majority of mammary gland development occurring 
postnatally (Gjorevski and Nelson, 2011; Hennighausen and Robinson, 2005). 
Embryonic mammary gland development 
The embryonic development of the human mammary gland is not well documented though 
much has been inferred from studies of the cognate murine mammary gland (Veltmaat et al., 
2013). In mice, the embryonic mammary development begins during mid-gestation and 
happens between embryonic days 10.5 and 18.5 (Hens and Wysolmerski, 2005; Robinson, 
2007). In all embryos (male and female), two ridges of multilayered ectoderm surface and form 
the milk lines. This is followed by the formation of five pairs of lens-shaped epithelial 
thickenings (placodes) that later sink into the mesenchyme forming mammary buds or anlagen 
(Sakakura et al., 1976). The mammary buds then sprout and branch, transforming into 
rudimentary ductal structures whose growth is essentially stopped from embryonic day 18 until 
puberty (Hens and Wysolmerski, 2005). In male mice there is regression of this undeveloped 
tissue in response to androgens, while in male humans the connection to the nipple is kept 
(Cardiff and Allison, 2012). 
Pubertal mammary gland development 
During puberty, high levels of ovarian hormones drive the most prominent stage of mammary 
branching morphogenesis (Lyons et al., 1958; Sternlicht, 2006). This is when the ends of the 
rudimentary ducts become multilayered epithelial structures, known as TEBs, where cap 
epithelial cells form an external layer that surrounds body epithelial cells (Hinck and 
Silberstein, 2005). TEBs are highly proliferative and lead the invading branch through the fat 
pad by successive elongation, bifurcation and lateral branching of the rudimentary ducts until 
the edge of the fat pad is reached (Silberstein and Daniel, 1982; Williams and Daniel, 1983) 
[Figure 2].  
Adult mammary gland development 
In adult females, the mammary epithelium and the surrounding stroma go through cyclical 
phases of remodeling and regeneration matching the hormonal changes of the menstrual cycle 
(Ramakrishnan et al., 2002). Specifically, the side branches along the primary and secondary 
mammary epithelial ducts form and vanish during each cycle (Hennighausen and Robinson, 
2005) [Figure 2]. Additionally, the mammary gland heavily changes during each cycle of 
pregnancy, lactation and involution, an ability that is maintained for several decades until 
menopause (Hennighausen and Robinson, 2005; Inman et al., 2015). During pregnancy, the 
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luminal epithelium undergoes rapid proliferation in response to circulating prolactin and 
differentiates into milk-producing secretory alveoli (Brisken et al., 1999; Oakes et al., 2008). 
Throughout lactation, milk proteins are produced and secreted by luminal epithelial cells into 
the lumen. Upon oxytocin release triggered by the suckling infant, the myoepithelial cells 
contract prompting the milk to flow through the ductal tree to the nipple (Forsyth and Neville, 
2009). Upon weaning, the stimuli for milk production are lost and vast apoptosis clears about 
80% of the epithelium during involution, the process that returns the gland to a pre-pregnancy 
state (Walker et al., 1989; Watson, 2006) [Figure 2]. 
Figure 2 | Macro- and microscopic organization and development of the murine mammary gland.      . 
(A) Illustration of the five pairs of bilaterally located murine mammary glands (three pairs positioned in the
cervicothoracic region and two pairs situated in the inguinoabdominal area).  . 
(B) Diagram emphasizing the gross morphological changes elicited by hormones during the murine estrous cycle.
(C) Schematic diagrams and representative mammary gland wholemounts showing the mammary gland
architecture and key morphological structures and hormones at the indicated postnatal stages of development.          .
(D) Histological sections matching the developmental stages specified above to highlight a pubertal TEB, an
organized adult duct, a lobule of a pregnant dam and milk-containing vacuoles of a lactating female. Upon
weaning, the mammary gland regresses to a nearly pre-pregnancy state (involution).
Panels A and D: Reprinted from Comparative Anatomy and Histology, First edition, Robert D. Cardiff, Kimberly H. Allison, 4 - Mammary Gland, Pages 41-52. 
Copyright (2012), with permission from Elsevier. .  
Panel B: From Tharmapalan et al., 2019 . 
Panel C: Reprinted by permission from Springer Nature: Nature Reviews Molecular Cell Biology Information networks in the mammary gland, Lothar Hennighausen 
et al., COPYRIGHT (2005) . 
6 
1.2.3 Integrated signaling in mammary morphogenesis 
Global endocrine hormones, such as estrogen and growth hormone secreted by the ovary and 
the pituitary, signal to mammary epithelial and stromal cells to convey the reproductive status 
of the system (Ramakrishnan et al., 2002). These endocrine hormones set in motion the 
crosstalk between the epithelium and the stroma by activating a plethora of local paracrine 
signaling to induce proliferation, survival and branching (Hennighausen and Robinson, 1998). 
Local paracrine signals comprise several growth factors and their cognate receptors including 
EGF, HGF, IGF1, and FGFR2 (Coleman et al., 1988; Kleinberg et al., 2000; Lu et al., 2008; 
Montesano et al., 1991; Parsa et al., 2008). Conversely, TGFβ serves as a negative regulator 
of mammary morphogenesis (Daniel et al., 1996). In addition to growth factors and their 
receptors, MMPs display distinct, spatially localized profiles of expression and activity 
(Wiseman et al., 2003). For instance, MMP14 is highly expressed in and around the TEBs 
while its inhibitor, TIMP3, is specifically downregulated at these sites (Szabova et al., 2005); 
both the epithelial cells and the stroma express low levels of MMP9 (Wiseman et al., 2003); 
MMP2 is least expressed at sites where lateral branching is likely to occur and MMP3 
expression is readily detected in the stroma (Wiseman et al., 2003). MMPs are key local 
regulators of mammary branching and patterning as indicated by several knockout mouse 
models (Sternlicht and Werb, 2001). Importantly, ECM degradation by MMP3 during 
involution, results in mammary epithelial cell death by anoikis (Lund et al., 1996).  
The mechanical features of the mammary cell microenvironment have been largely neglected 
in the past, but it is now increasingly evident that matrix stiffness influences the mammary 
epithelial phenotype (Levental et al., 2009; Paszek et al., 2005; Schedin and Keely, 2011). For 
instance, when mammary epithelial cells are grown on floating three-dimensional collagen 
gels, they self-organize into tubules but fail to do so if attached to collagen-coated culture dishes 
(with a typical stiffness ranging between 1 and 2 GPa) (Wozniak et al., 2003). Similarly, 
mammary epithelial cells can produce milk proteins in soft ECM resembling the normal breast 
environment (typically 400 Pa) but not in more rigid contexts (Alcaraz et al., 2008).  
Thus, depending on the exact location of a cell within the epithelial tree, it will be subjected to 
a specific environment governing a context-dependent functional response.  
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1.3 THE PANCREAS 
1.3.1 The anatomy and physiology of the pancreas 
The pancreas is a combined endocrine and exocrine glandular organ that regulates systemic 
blood sugar levels through the secretion of hormones and participates in food digestion via 
secretion of digestive enzymes (Dintzis and Liggitt, 2012).  
The pancreas of an adult human is solid, white-to-pink-colored, approximately 12–15 
centimeters long, 2–9 centimeters wide, weights approximately 50–100 grams and lies in the 
upper left part of the abdomen, in close association with the upper duodenum (Bockman, 1993) 
[Figure 3]. Three macroscopically distinct parts can be identified in the human pancreas: a C-
shaped head aligned with the upper curvature of duodenum; a tail that contacts the hilum of the 
spleen and a flat narrow body that extends almost horizontally under the stomach (Suda et al., 
2006). In mice, the pancreas is rather a diffusely distributed soft tissue (Dolensek et al., 2015). 
Two distinct compartments have been identified that relate to the pancreas function as an 
endocrine and exocrine glandular tissue (Bardeesy and DePinho, 2002) [Figure 3]. 
Figure 3 | Endocrine and exocrine pancreatic compartments and constituent cell types. . 
(A) Schematic macro- and microscopic organization of the adult human pancreatic compartments. i. The regional
anatomy of the human pancreas. ii. Schematic wholemount view of the exocrine pancreas. iii. Cross-section
highlighting exocrine cells. iv. Cross-section highlighting an endocrine Islet of Langerhans and its resident cells.
(B) Histological sections of human and murine pancreatic tissues.
Panel A: Reprinted by permission from Springer Nature: Nature Reviews Cancer Pancreatic cancer biology and genetics, Nabeel Bardeesy et al., COPYRIGHT 
(2002) 
Panel B: Reprinted from Comparative Anatomy and Histology, First edition, Robert D. Cardiff, Kimberly H. Allison, 14 - Pancreas, Pages 41-52., Copyright (2012), 
with permission from Elsevier. 
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The exocrine pancreatic compartment makes up over 95% of the pancreatic tissue (Ellis et al., 
2017). In the exocrine pancreatic compartment, acinar cells secrete nutrient-digestive enzymes 
such as trypsin and amylase that are transported through a ductal epithelial system into the 
duodenum (Bardeesy and DePinho, 2002). The endocrine pancreatic compartment is organized 
in discrete islets of Langerhans that are composed of multiple cell types that secrete various 
hormones into the bloodstream (Bardeesy and DePinho, 2002). Specifically, glucagon is 
secreted by α-cells; insulin is secreted by β-cells; somatostatin by δ-cells; ghrelin by ε-cells and 
pancreatic polypeptide is secreted by γ [or PP]-cells (Pan and Wright, 2011; Shih et al., 2013). 
Aberrant function of these cell populations has been linked to both endocrine pancreatic 
disorders (like diabetes mellitus and endocrine cancer) and exocrine diseases (such as 
pancreatitis and pancreatic adenocarcinoma) (Dunne and Hezel, 2015; Murtaugh and Keefe, 
2015). The widespread prevalence of these diseases provides incentive for continued efforts to 
broaden our understanding of pancreatic biology that might ultimately pinpoint molecular 
targets for therapy (Dunne and Hezel, 2015; Murtaugh and Keefe, 2015) 
 
1.3.2 Pancreas development  
As with the study of the mammary gland, our understanding of pancreas organogenesis has 
relied on the mouse as a model to infer fundamental aspects (Jennings et al., 2015).  
The pancreas derives from dorsal and ventral buds that outgrow from either side of the 
primitive foregut endoderm (Zaret and Grompe, 2008). Induction of Pdx1 expression at 
embryonic day 8.5 is one of the first signs of pancreas development (Guz et al., 1995), followed 
by Ptf1a expression at embryonic day 9.5 (Kawaguchi et al., 2002). From embryonic days 9.5 
to 12.5 cells express both Ptf1a and Pdx1 (Burlison et al., 2008) and further differentiate to 
generate the cell lineages that ultimately originate all types of pancreatic cells that fulfill its 
different physiological roles (Bastidas-Ponce et al., 2017; Benitez et al., 2012; Stanger et al., 
2007).  
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1.4 CANCER 
Cancer has occurred since antiquity (David and Zimmerman, 2010). The Edwin Smith Papyrus, 
written around 1600 B.C. in Ancient Egypt, provides some of the earliest descriptions of cancer 
(Breasted et al., 1930) and evidences for the disease have been found in various archeological 
and paleontological specimens (David and Zimmerman, 2010). Specifically, an osteosarcoma 
diagnosed in a fossilized foot bone found in the Cradle of Humankind (the fossil-rich region of 
South Africa), stands as the earliest known cancer case and dates back to approximately 1.7 
million years ago (Franklin et al., 2016). Hippocrates, “the Father of Medicine”, first named 
masses of cancer cells “karkinos”, the Greek word for crab around 400 B.C. (Hajdu, 2011). 
Later on, approximately 28-50 B.C., “karkinos” was translated to Latin, “cancer”, by the 
Roman physician Celsus (Hajdu, 2011). Around 130-200 A.D., the word “oncos” (meaning 
swelling in Greek) was used by the Greek physician Galen to describe tumors and this prefix 
is still prevalent in disease-related terms such as oncology or oncologist (Hajdu, 2011).  
Our understanding of cancer, as its nomenclature, has also been evolving over time. Today, we 
no longer refer to cancer as one single disease, but rather as a large group of disorders (often 
also called malignant tumors or neoplasms) (Weinberg, 2006). We also consider cancer as a 
disease of malfunctioning cells that no longer create the form and function characteristic of a 
normal tissue and that disobey the rules of tissue formation and maintenance (Weinberg, 2006). 
Cancer cells deviate in behavior from their normal counterparts in a spectrum of “in betweens”, 
progressively away from normal and towards varying degrees of abnormality and 
aggressiveness (Weinberg, 2006). We are also more aware that tumors contain many cell types 
that interact and co-evolve with the cancer cells and the local environment, thereby contributing 
to the complexity of the disease (Hanahan and Weinberg, 2000, 2011).  
Despite being an “old” disease (David and Zimmerman, 2010) that has been and continues to 
be extensively studied, fundamental questions linger unresolved and cancer continues to be a 
heavy burden worldwide. The estimates from the World Health Organization speak for 
themselves: worldwide, cancer is the second leading cause of death, accounting for 
approximately 9.6 million (1 in 6) deaths in 2018 and globally, it is expected that one in five 
men and one in six women will develop cancer during their lifetime, with 1 in 8 and 1 in 11, 
respectively, dying from the disease (Bray et al., 2018). Thus, substantial efforts must be 
channeled into cancer research to get us better at preventing, diagnosing and curing cancer 
(Song et al., 2018; Wild et al., 2019).  
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1.4.1 Breast cancer 
According to the World Health Organization, breast cancer is the most commonly diagnosed 
cancer in women worldwide (24.2 % of all new cancers) and it is also the leading cause of 
cancer death in women (15 %) (Bray et al., 2018).  
Substantial advances have been made in our understanding of breast cancer over the past 50 
years and women diagnosed with breast cancer today, who can access adequate treatment, face 
a much lower mortality risk compared to the past (Hayes, 2019). However, this is still not the 
case after metastatic spread (Tevaarwerk et al., 2013). The understanding that breast cancers 
are biologically different and, as such, amenable to a semi-personalized treatment, is largely 
behind the relatively successful management of local breast cancer (Hayes, 2019). Dated 
classification of breast cancers was based on positivity for the hormone receptors for estrogen 
and progesterone (nearly 70 % of cases), expression of ERBB2/HER2 (nearly 15 % of 
patients), or negativity for all three markers and thus named triple-negative (the remaining 15 
%) (Waks and Winer, 2019). More recently, five major subtypes of breast cancer have been 
identified (Perou et al., 2000; Sorlie et al., 2001) discernible by the expression of 50 genes 
(PAM50) as basal-like, luminals A and B, normal-like and ERBB2/HER2 (Parker et al., 2009). 
Moreover, even more refined clusters of breast cancer have been derived (Curtis et al., 2012).  
Breast cancer is often diagnosed on a screening mammogram or by detection of a palpable 
mass in the breast or axillary region and it is generally non-metastatic at diagnosis (Waks and 
Winer, 2019). Clinical management of early stage breast cancers aims to eradicate the primary 
tumor and prevent its recurrence with surgical resection, postoperative radiation and systemic 
therapies determined by the tumor subtype (Waks and Winer, 2019). Patients carrying tumors 
that are positive for hormone receptor usually benefit from systemic endocrine (anti-estrogen) 
therapy that counteracts the estrogen-supported tumor growth. Depending on the menopausal 
status, systemic endocrine treatment consists of tamoxifen (that competes with estrogen for 
binding the receptor) or aromatase inhibitors such as anastrozole, exemestane, and letrozole 
(that inhibit the conversion of androgens to estrogen and thus reduce circulating estrogen 
levels) (Ignatiadis and Sotiriou, 2013). Patients with tumors expressing ERBB2 may benefit 
from treatment with the humanized monoclonal antibody directed against HER2 (trastuzumab) 
or small-molecule tyrosine kinase inhibitors (Gingras et al., 2017). The choice of the systemic 
therapy, the treatment schedules and the combination of multiple agents is still a matter of 
ongoing research to optimize clinical outcome and minimize the adverse effects that often 
accompany the therapy (Ponde et al., 2019; Richman and Dowsett, 2019). Additionally, 
specific criteria help to pre-emptively identify women at high risk of developing breast cancer 
(Tharmapalan et al., 2019). 
Heterogeneous expression of molecular markers has also been noted within the same tumor 
and discordance between primary tumors and their metastases has also been observed 
(Lindstrom et al., 2012). Thus, both inter- and intratumor heterogeneity are pronounced 
features of breast cancers that complicate the clinical management of the disease (Zardavas et 
al., 2015).  
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1.4.2 Hallmarks of cancer 
Back in the year 2000, Douglas Hanahan and Robert Weinberg proposed the hallmarks of 
cancer: a list of six common traits or capabilities shared by cancer cells that facilitate the growth 
of tumors and their metastatic spread (Hanahan and Weinberg, 2000). A decade later, the list 
of hallmarks was updated (Hanahan and Weinberg, 2011). Their publications also featured the 
categorical role played by the microenvironment in tumorigenesis and provided a remarkable 
framework that helped the scientific community to rationalize the abysmally complex biology 
of cancer [Figure 4]. 
Figure 4 | The hallmarks of cancer according to Douglas Hanahan and Robert Weinberg.                                          . 
Schematic diagram showing the 6 core hallmarks (1-6), the 2 emerging hallmarks (a-b) and the 2 enabling 
characteristics (A-B) shared by cancer cells. Key features of each represent potential therapeutic opportunities. 
(1) Sustaining Proliferative Signaling. The first hallmark poses that cancer cells are self-sufficient in growth
signals, i.e. they can stimulate their own growth. (2) Evading growth suppressors. Cancer cells are insensitive to
inhibitory signals that might otherwise stop their growth. (3) Resisting cell death. Cancer cells are able to evade
programmed cell death mechanisms such as apoptosis. (4) Enabling replicative immortality. Cancer cells
express telomerase that confers them with limitless replicative potential; they can multiply virtually indefinitely.
(5) Inducing angiogenesis. Cancer cells stimulate blood vessel growth for nutrient replenishment. (6) Activating
invasion and metastasis. Cancer cells can locally invade the tissue and spread to noticeably distant sites. (a)
Deregulating cellular energetics. Cancer cells display abnormal metabolic pathways. (b) Avoiding immune
destruction. Cancer cells can evade elimination by the immune system. (A) Genome instability and mutation,
that generate diversity. (B) Tumor-promoting inflammation, that promotes several of the hallmarks of cancer.
Reprinted from Hallmarks of Cancer: The Next Generation, 144, Douglas Hanahan & Robert A. Weinberg, Hallmarks of Cancer: The Next Generation, Pages 646-
674, Copyright (2012), with permission from Elsevier. 
12 
1.5 CELLULAR SENESCENCE 
In 1961, Leonard Hayflick and Paul Moorhead coined the term “cellular senescence” when 
describing that primary normal human fibroblasts have a limited proliferative capacity (of 
about 50 to 60 population doublings) when propagated in culture (Hayflick and Moorhead, 
1961). At that time, their work was rejected by a prominent journal and their observation was 
considered an artifact by a scientific community devoted to the dogma that cultured cells 
replicate indefinitely if provided the proper milieu in vitro (Shay and Wright, 2000). 
Eventually, the Nobel Prize–winning discovery of telomerase and telomere shortening (Greider 
and Blackburn, 1985, 1989; Szostak and Blackburn, 1982) provided an explanation to the so-
called “Hayflick limit”. It is now recognized that proliferating normal cells that lack telomerase 
expression undergo progressive telomere erosion with every cell division that ultimately 
exposes an uncapped chromosome end triggering a permanent DDR (Shay, 2016). This 
establishes “replicative senescence” or “premature senescence”, that halts the proliferation of 
these damaged cells (Shay, 2016). Senescence has since been assumed to contribute to aging, 
but this was only attested when selective elimination of p16INK4A-positive senescent cells 
delayed ageing-associated disorders (Baker et al., 2011) and extended the lifespan of mice 
(Baker et al., 2016). Subsequently a wide range of cellular stressors / triggers including 
persistent DNA damage caused by cytotoxic agents, epigenomic alterations and oxidative 
stress have been shown to evoke a phenotypically similar senescence response (Collado and 
Serrano, 2010).  
Strikingly, normal cells also responded to oncogene activation by undergoing senescence, a 
phenomenon known as OIS (Serrano et al., 1997). Similarly, loss of tumor suppressors such as 
PTEN or the activation of classic cell cycle inhibitors such as p16INK4A also induced a 
senescence response (Collado and Serrano, 2010). However, the physiological relevance of 
OIS was questioned until the identification of senescent cells in pre-malignant / benign states 
(such as the nevus or colon adenoma) and their scarcity in subsequent established tumors 
(melanoma or the colon carcinoma, respectively) (Braig et al., 2005; Chen et al., 2005; 
Michaloglou et al., 2005). These studies therefore suggested that the senescence program can 
potently prevent cancer by acting as a major barrier to tumorigenesis in vivo (Collado et al., 
2005; Narita and Lowe, 2005) [Figure 5]. The capacity to overcome senescence has since been 
postulated as a crucial step in the progression from pre-malignant to malignant, but it remains 
to be elucidated if tumors arise as a consequence of a true senescence bypass or escape (Braig 
and Schmitt, 2006).  
Cellular senescence is thus a general stress-inducible process that imposes a proliferative arrest 
on damaged cells and complements apoptosis in the maintenance of tissue homeostasis (Rodier 
and Campisi, 2011). Given that tumors often present with defective apoptotic machinery, 
senescence is considered an additional safeguard tumor suppressing mechanism (Rodier and 
Campisi, 2011). Additionally, senescent cells remain viable and can either be cleared by the 
immune system or accumulate in the tissues (Munoz-Espin and Serrano, 2014) supporting the 
notion of senescence as an example of antagonistic pleiotropy: a beneficial process that helps 
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preventing cancer at young age but that becomes detrimental later in life, contributing to age-
related decline (Campisi, 2005). However, recent studies showed that cellular senescence also 
plays fundamental roles, mediated by the secretome, during embryonic development (Munoz-
Espin et al., 2013), in cellular reprogramming / plasticity (Banito et al., 2009; Mosteiro et al., 
2016) and in tissue repair and regeneration (Demaria et al., 2014), thereby suggesting 
senescence as a broad tissue remodeling process both in normal physiology and pathology 
(Munoz-Espin and Serrano, 2014; Rhinn et al., 2019). 
Figure 5 | Oncogene-induced senescence as a barrier to tumorigenesis.  . 
(A) Schematic diagram illustrating how the OIS barrier may be overcome. Upon oncogene activation, normal cells
undergo an initial phase of aberrant cell proliferation (purple cells) that is followed by the establishment of
senescence, specifically OIS (blue cells). If intact, the senescence program can restrict the growth of the pre-
malignant lesion. However, additional events may disable the senescence program (i.e. loss of tumor supressors),
and cells may overcome the senescence barrier and form malignant tumors (red cells).
(B) Histological lung section showing abundant SA-β-gal activity (blue) in a pre-malignant KRAS-driven lung
adenoma (top) in sharp contrast with a largely negative malignant lung adenocarcinoma (bottom). The inset
represents the negative control.
Panel A: Reprinted by permission from Springer Nature: Nature Medicine Senescence comes of age, Masashi Narita et al., COPYRIGHT (2005) . 
Panel B: Reprinted by permission from Springer Nature: Nature Senescence in premalignant tumours, Manuel Collado et al., COPYRIGHT (2005) . 
1.5.1 The senescent phenotype 
The phenotype of senescent cells is heterogeneous as diverse triggers can provoke it and 
various mechanisms can enforce it (Hernandez-Segura et al., 2018). Importantly, the traditional 
view of cellular senescence as a static state has now been challenged and senescence starts to 
be perceived as a dynamic process (Hoare et al., 2016; Schmitt, 2016). 
To date, there are no senescence-specific and universal markers (Sharpless and Sherr, 2015). 
Instead, senescent cells are often characterized by multiple features including a flattened 
morphology in vitro, a durable proliferative arrest accompanied by the ‘gold-standard’ 
increased activity of lysosomal SA-β-gal (Dimri et al., 1995) and a plethora of secreted pro-
inflammatory cytokines and chemokines (referred to as SASP or SMS) (Acosta et al., 2008; 
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Coppe et al., 2008; Kuilman et al., 2008). Various other potential senescence markers have 
been proposed over the years including the loss of LAMIN B1 (that compromises the integrity 
of the nuclear membrane) and associated presence of chromatin fragments in the cytoplasm, 
overexpression of anti-apoptotic BCL-2 family members (conferring apoptosis resistance) and 
metabolic changes (Hernandez-Segura et al., 2018).  
 
1.5.2 Pro-senescence therapies and the two-hit synthetic lethal strategies 
The secretome of senescent cells reinforces the senescence-associated growth arrest via an 
autocrine loop and may, in a paracrine way, induce senescence in surrounding cells, recruit the 
immune system for self-clearing or i.e. promote cancer in neighboring cells (McHugh and Gil, 
2018). So, in essence, cellular senescence plays primarily an advantageous tumor-suppressive 
role but, in the long term, senescent cells are potentially detrimental due to SASP-related 
chronic inflammation and the risk of neoplastic conversion of nearby cells (Faget et al., 2019). 
Thus, researchers are attempting two-hit synthetic lethal strategies that first induce a senescence 
response in tumors followed by selective elimination of these cells (Dorr et al., 2013). These 
strategies have shown some success elegantly demonstrated by the laboratories of Van Deursen 
using the ‘INK-ATTAC’ transgenic mouse (Baker et al., 2011) and Campisi using the p16-
3MR mouse (Demaria et al., 2017; Demaria et al., 2014). Additionally, a very active branch of 
research works towards the development of senolytics, small-molecule compounds that can 
selectively eliminate senescent cells (Wang et al., 2019). Examples include ruxolitinib and 
dasatinib (tyrosine kinase inhibitors) and ABT-263 (inhibitors of the anti-apoptotic BCL2 
family) but their true usefulness in clinical settings remains to be seen (Zhu et al., 2015). 
 
1.5.3 NF-κB signaling in senescence 
The NF-κB family of transcription factors is composed of five subunits (NFKB1, NFKB2, 
RELA, RELB and C-Rel) that form homo and heterodimers and regulate the expression of a 
wide spectrum of pro-inflammatory genes (Zhang et al., 2017). 
NF-κB signaling has traditionally been differentiated into canonical / classical and non-
canonical / alternative depending on the subunits actively involved (Cildir et al., 2016). In 
canonical NF-κB signaling, RELA-p50 heterodimers accumulate in the nucleus following the 
cleavage of NFKB1 into active p50 form. The processing of NFKB2 into p52 and assembly of 
RELB-p52 complexes characterizes the non-canonical NF-κB pathway (Perkins, 2012). 
NF-κB (specifically canonical, RELA-mediated) acts a master regulator of the SASP (Chien et 
al., 2011; Jing et al., 2011) as many of the SASP components are bona fide NF-κB targets 
genes (Acosta et al., 2008; Coppe et al., 2008; Kuilman et al., 2008).  
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1.6 PAK SIGNALING IN DEVELOPMENT AND CANCER 
1.6.1 The PAK family 
PAKs were first discovered in 1994 by Ed Manser in the laboratory of Louis Lim when 
screening for proteins that interacted with GTP-bound Rac in rat brain (Manser et al., 1994). 
Since then, a total of six family members have been identified in mammals (PAKs 1 to 6) that 
are evolutionarily conserved (Kumar et al., 2017). Mammalian PAKs distribute across two 
subgroups based on sequence homology and structural differences: the first subgroup includes 
PAKs 1–3 and the second subgroup comprises PAKs 4–6 (Chan and Manser, 2012). All PAKs 
display a GTPase- (or p21-) binding domain (GBD / PBD) at the N-terminus and a 
serine/threonine kinase domain at the C-terminus half that share approximately 50% homology 
among the family members (Eswaran et al., 2008; Radu et al., 2014). Despite the similarity 
among PAK gene sequences and their core structures, PAKs exhibit distinct mechanisms of 
activation where group I PAKs have an AID and require activation, whereas group II PAKs 
contain an AID-like pseudosubstrate domain and are constitutively active (Kumar et al., 2017) 
[Figure 6].  
Our understanding of the biology of PAKs has been greatly influenced by discoveries regarding 
the founding members of the family subgroups, PAK1 (Manser et al., 1994) and PAK4 (Abo 
et al., 1998), that are also the most widely studied PAKs (Dart and Wells, 2013). A large body 
of literature has shown that PAKs can localize in several subcellular compartments and exert 
their functions through their kinase activity and/or as scaffold-adaptor proteins (Kumar et al., 
2017). PAKs receive numerous extracellular and intracellular signals and convey the message 
via several PAK interacting proteins, downstream substrates and genomic targets, ultimately 
leading to a phenotypic response (Radu et al., 2014). PAKs have different expression patterns 
in different tissues (Rane and Minden, 2019) and have both overlapping and unique substrates 
(Kumar et al., 2017) [Figure 6]. Likewise, they have overlapping and unique functions as 
supported by gene knockout studies. For instance, PAK1 knockout mice are viable and fertile 
while PAK2 knockout mice are embryonically lethal (Arias-Romero and Chernoff, 2008) and 
PAK3 knockout mice exhibit mental retardation (Meng et al., 2005). Additionally, PAK4 
knockout mice die in early embryonic developmental stage (E11.5) due to heart and neural tube 
defects (Qu et al., 2003) while PAK5, PAK6 and double PAK5/PAK6 knockout mice are all 
viable and fertile (King et al., 2014). This thus suggests that PAK2 and PAK4 functions cannot 
be fully compensated for by other members of the PAK family. 
Understandably, abnormalities in PAK signaling disrupt cellular homeostasis and impact 
cellular functions, with consequences in a vast number of human diseases that span from 
neurological disorders, to cardiac disease and cancer (Kumar et al., 2017). 
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Figure 6 | The family of p21-activated kinases . 
(A) Schematic diagram of the structural domains of group I and II PAKs. All PAKs share a high degree of 
similarity at the N-terminus and kinase domain but subgroups show distinct autoinhibitory domains.
(B) Illustration summarizing recognized PAK substrates and their roles in cancer hallmarks. While there is some 
overlap between the groups, subgroup-specific substrates have been identified. 
Panel A: Reprinted from Advances in Cancer Research, 130, R. Kumar, D.-Q Li, PAKs in Human Cancer Progression: From Inception to Cancer Therapeutic to 
Future Oncobiology, Pages 137-209, Copyright (2016), with permission from Elsevier.  .  
Panel B: Reprinted by permission from Springer Nature: Nature Reviews Cancer PAK signaling during the development and progression of cancer, Maria Radu, 
Galina Semenova, Rachelle Kosoff, Jonathan Chernoff, COPYRIGHT (2013) .  
1.6.2 PAK4 and the hallmarks of cancer 
A large body of literature shows that PAKs-mediated signaling is vital to a variety of hallmarks 
of cancer (Radu et al., 2014) [Figure 6]. The same applies to PAK4. Succinctly, PAK4 
promotes anchorage independent growth (Callow et al., 2002; Qu et al., 2001), protects cells 
from certain apoptotic stimuli (Gnesutta and Minden, 2003; Gnesutta et al., 2001) and has a 
well proven role in the regulation of cell adhesion and migration namely, through interaction 
with αvβ5 integrin to regulate adhesion dynamics (Li et al., 2010a; Li et al., 2010b; Zhang et 
al., 2002). Moreover, several studies provide evidence to suggest that PAK4 is involved in 
controlling several aspects of proliferation (Dart and Wells, 2013; Rane and Minden, 2019) 
and contributes to drug-resistance (Moon et al., 2015; Zhuang et al., 2015). 
1.6.3 Clinical relevance of PAK4 in cancer 
Human cancer cell lines originated from various tissues frequently display PAK4 
overexpression (Callow et al., 2002). The same is true for the more tumorigenic cell lines of 
the MCF10A progression series (So et al., 2012). Importantly, PAK4 overexpression has been 
reported in several human tumors. These include a small set of human breast cancer specimens 
(Bi et al., 2016; He et al., 2017; Liu et al., 2010), pancreatic cancer (Tyagi et al., 2014), ovarian 
cancer (Siu et al., 2010), prostate cancer (Park et al., 2018), gallbladder cancer (Kim et al., 
2008), gastric cancer (Ahn et al., 2011; Kobayashi et al., 2016), endometrial cancer (Siu et al., 
2015), gliomas (Kesanakurti et al., 2012) and hepatocellular carcinoma (Xu et al., 2016). 
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In some instances, PAK4 overexpression has been correlated to PAK4 gene amplification such 
as in pancreatic (Chen et al., 2008; Kimmelman et al., 2008) and ovarian cancers (Davis et al., 
2013). Even though the PAK4 gene sits in a chromosomal region (19q13.2) frequently 
amplified in basal-like breast cancers (Yu et al., 2009), PAK4 amplification was only detected 
in about 2 % of TCGA breast tumors (Kumar and Li, 2016).  
Notably, high levels of PAK4 expression correlate to poor patient prognosis in ovarian cancer 
(Siu et al., 2010), non-small cell lung cancer (Cai et al., 2015; Wang et al., 2016), gastric cancer 
(Kobayashi et al., 2016), endometrial cancer (Siu et al., 2015), prostate cancer (Park et al., 
2018) and in endocrine-positive breast cancer patients (Li et al., 2019; Santiago-Gomez et al., 
2019; Zhuang et al., 2015).  
1.6.4 Inhibitory molecules targeting PAK4 
Given the established links between PAK4 and cancer, great efforts are ongoing to develop 
PAK4 inhibitory molecules to be used as either first line or adjuvant cancer treatment (Rane 
and Minden, 2019).   
Nearly a decade ago, Pfizer developed PF-3758309, an ATP-competitive inhibitor that potently 
binds PAK4, inhibits PAK4-dependent phosphorylation of GEFH1 and reduces proliferation 
and anchorage-independent growth across a panel of cancer cells of diverse origin (Murray et 
al., 2010). Despite designed to specifically target PAK4, PF-3758309 showed broad activity 
towards other PAKs and other members of the kinome (Murray et al., 2010). Unfortunately, it 
failed to progress past an early-phase human clinical trial due to undesirable pharmacokinetic 
characteristics, namely poor bioavailability with accompanying lack of tumor response and 
adverse side effects (Thillai et al., 2018). 
Compound 17 (also known as GNE-2861) is a potent inhibitor developed by Genentech that 
demonstrates selectivity for group II PAKs (Staben et al., 2014). It reduces viability, decreases 
migration and invasion and enhances tamoxifen-sensitivity (Zhuang et al., 2015). 
Disappointingly, this compound also shows poor bioavailability that may be due to poor 
permeability and/or high efflux (Rudolph et al., 2015). 
A number of additional inhibitors of PAK4/PAKs activity have been reported. LCH-779944 
has yet to be tested in vivo but it has been shown to inhibit PAK4 kinase activity and reduce 
cell proliferation and invasion (Rane and Minden, 2019). 
More recently, a novel class of PAK4 allosteric modulators (KPT-8752 and KPT-9274) has 
been presented that reduce PAK4 protein levels, rather than only targeting PAK4 kinase 
activity, most likely by binding to and destabilizing the protein (Abu Aboud et al., 2016; Rane 
et al., 2017). Given the kinase-independent functions reported for PAK4 and the fact that the 
protein is often overexpressed in cancer, such compounds could prove useful in a cancer 
setting. KPT-9274 is currently in phase I clinical trial (NCT02702492).  
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2 AIMS 
General aim 
Signaling by PAK kinases regulates central aspects of tissue homeostasis. The research articles 
included in this thesis contribute novel evidence towards a better understanding of the role of 
PAK4 in normal mammary gland and pancreatic function and in breast cancer, provide novel 
transgenic mouse models to study PAK4 signaling in health and disease and propose original 
mechanistic insight.  
Specific aims 
Paper I: To develop a novel transgenic mouse model with conditional PAK4 depletion in the 
mammary epithelium and to characterize its phenotype.  
Paper II: To develop a novel transgenic mouse model with conditional PAK4 depletion in the 
pancreas and to characterize its phenotype.  
Paper III: To elucidate novel functions and signaling mechanisms of PAK4 in breast cancer. 
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3 METHODOLOGICAL CONSIDERATIONS 
Detailed descriptions of the materials and methods can be found in the corresponding papers. 
This section rather brings up some general considerations, advantages and limitations regarding 
the experimental models used in this thesis. 
3.1 TOOLKIT FOR STUDYING DEVELOPMENT AND DISEASE 
A variety of tools are available to the present-day scientist to modulate and study 
protein/cellular function in vitro, in vivo and ex vivo and several experimental model systems 
are currently available to study developmental and cancer biology.  
The various experimental models range from in vitro to in vivo setups and largely vary in 
complexity. One important aspect is that models should be seen as complementary, with each 
model presenting benefits and weaknesses when used to address specific questions. It is thus 
important to identify the optimal model for the right purpose, making compromises, and to 
acknowledge that reductionist approaches are often needed to untangle and understand the 
contributions and interactions of the various components to a level that wouldn’t be achievable 
i.e. in more physiological in vivo settings.
For example, in Paper III, we have used various animal models (transgenic mice and 
xenografts), primary and established cancer cell lines, patient-derived cells and even 
recombinant proteins to test hypotheses using laboratory techniques that ranged from more 
traditional and reductionist (such as radioactive kinase assays) to state-of the art and global 
methods (such as exome and RNA-Sequencing). Additionally, clinical datasets were used to 
identify correlations, with hopes that such a broad approach would be better to unravel potential 
roles of PAK4 in breast cancer. 
3.1.1 Cell lines 
The first human cancer-derived cell line, HeLa, was established in 1951 from cervical cancer 
cells harvested from Henrietta Lacks (Masters, 2002). Ever since, a large number of cancer cell 
lines have been established from many tumor types and various panels of cancer cell lines per 
tumor type have been assembled (such as the National Cancer Institute NCI-60 panel) 
(Shoemaker, 2006). Cancer cell lines have been traditionally grown on artificial 2D monolayers 
on plastic, substantially missing important features of the complex tumor microenvironment, 
and thus constitute an obviously reductionist model system of cancer. Nevertheless, cell lines 
are relatively easy to propagate and manipulate in the laboratory, low cost and therefore remain 
widely used and an important source of information.  
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It is important to keep in mind that clonal evolution and positive selection continues in culture 
leading to cell divergence over time, which helps to explain why different stocks of widely 
used cancer cell lines are highly heterogeneous in their genome, transcriptome and response to 
therapies (Ben-David et al., 2018). Thus, it is of utmost importance to control the origin, culture 
growth conditions, the cumulative passaging of cells and eventual contaminants (i.e. 
mycoplasma) to minimize their influence in experimental outcomes. Additionally, when 
plausible, experiments should be carried out in a microenvironment that better mimics the 
original cell context. To this end, systems that have been developed include 3D organoid 
cultures, the use of various ECM coatings and substrates of varied stiffness or modulation of 
oxygen to more physiological levels. 
To overcome some of the limitations of cancer cell lines, scientists have been adopting patient-
derived cancer models that are closer to the patient and thus more likely to reflect the patient's 
disease (Hidalgo et al., 2014). However, these models are likely more heterogeneous and still 
subjected to the same evolutionary pressures during propagation. 
Normal cells, cancer cell lines of various origins and patient-derived cells have been used in 
Paper III to test in vitro and ex vivo effects of PAK4 depletion or overexpression and to 
identify the molecular mechanisms involved. Detailed characteristics of the breast cancer cell 
lines used can be found in the Supplementary Table 1 of Paper III. 
. 
3.1.2 Mouse models 
Despite the ethical concerns that involve experiments with laboratory animals, the study of 
tissue development and tumorigenesis commonly employs mouse models where cells of 
interest are within a more natural environment. All three papers included in this thesis 
extensively relied on mouse models to derive new knowledge. Fortunately, the use of 
laboratory animals in Sweden requires well-founded ethical permission and obeys to very high 
standards of animal welfare. Reducing the number of required animals and minimizing their 
potential suffering should nevertheless always be in the mind of the researcher.  
Cell line-derived models 
The most commonly used mouse models in basic and translational cancer research rely on the 
inoculation into mice of in vitro expanded cancer cells (Gengenbacher et al., 2017). Murine 
cancer cells can be allografted into syngeneic, immunocompetent mice while human cancer 
cells can be xenografted into immunocompromised mice. Depending on the route of 
inoculation, tumors then form relatively fast and synchronously subcutaneously (thus more 
easily monitored), orthotopically (better mimicking tumor growth in its original organ) or 
systemically (if cells are intra-peritoneally, intravenously or intracardially injected for studying 
metastatic disease). The use of a standard cell line may present as advantageous by resulting in 
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a more homogenous response within treatment groups, thus facilitating comparisons and 
conclusions. Additionally, cancer cells can be manipulated in vitro prior to inoculation or 
established tumors can be subjected to treatments. Breast cancer cells with stable PAK4 
knockdown or control cells were xenografted onto the back of immunodeficient mice in Paper 
III, to validate in vivo the previously acquired in vitro data.  
Genetically engineered mouse models 
Genetically engineered mouse models inform on the biological role of genes in a physiological 
context and rank as the second most commonly used mouse model in cancer research 
(Gengenbacher et al., 2017).  
The most common strategies for generating genetically engineered mice include transgene 
overexpression and conventional or conditional gene knockin and knockout. The latter were 
only possible due to the isolation of mouse embryonic stem cells and the groundbreaking 
discovery of homologous recombination (Capecchi, 2001; Evans, 2001; Smithies, 2001).  
In conventional knockouts, the gene of interest is inactivated by disrupting its open reading 
frame thus blocking its expression or, alternatively, by deleting critical exons for gene function. 
Constitutive knockout may cause embryonic lethality, if the gene is essential during 
development, and impede further investigation beyond a specific embryonic stage. This is the 
case in mice with constitutive PAK4 knockout (Qu et al., 2003). To overcome this problem, 
conditional mouse models were generated based on the Cre/loxP system (that relies on site-
specific recombinase) and allow a spatially and temporally controlled gene expression (Kim et 
al., 2018). This strategy has been employed to study PAK4 in vivo after embryonic day 11.5 
(Nekrasova and Minden, 2012; Tian et al., 2009; Tian et al., 2011).  
This thesis contributes three novel PAK4 mouse models: two conditional knockouts with 
PAK4 depletion in the mammary epithelium (Paper I) and in the pancreas (Paper II) and a 
mouse model with PAK4 overexpression in the mammary epithelium (Paper III). 
MMTV-LTR, WAP, BLG and cytokeratin 14 are promoters commonly used to drive 
expression of a gene in the murine mammary epithelial cells. Among these, MMTV-LTR is 
the most frequently used promoter given its activity in both virgin and lactating females 
(Vargo-Gogola and Rosen, 2007). This was also the reason why the MMTV-LTR promoter 
was chosen to express Cre and PAK4 in the mammary epithelium in Paper I and in Paper III, 
respectively. It is important to remember that MMTV-LTR expression is sensitive to steroid 
hormones and peaks during lactation (Taneja et al., 2009) which may be important when 
interpreting data derived from models with MMTV-driven gene expression. Apart from 
targeting expression to the mammary epithelium, MMTV-driven expression is often detected 
in salivary glands, seminal vesicles, skin, erythrocytes, B cells and T cells while little 
background was observed in the lung, kidney, liver and brain tissues (Henrard and Ross, 1988). 
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Thus, caution may be needed if expression in any of these additional organs can constitute a 
confounding factor.  
Several transcription factors have been used to create pancreas-specific mouse models. They 
include cytokeratin 19, nestin, elastase, Mist1, Ptf1a (or p48) and Pdx1 (Magnuson and 
Osipovich, 2013). The Pdx1 promoter was chosen in Paper II to drive Cre expression in 
pancreatic tissues given its early expression in embryonic development (E8.5), thus targeting 
both endocrine and exocrine pancreatic cells.  
Genetically engineered mouse models have significantly contributed to our understanding of 
breast cancer initiation and progression because they represent cancer as an evolutionary 
process where cancer cells develop and grow within their local and systemic environment 
(Vargo-Gogola and Rosen, 2007). However, it is important to emphasize that none of the 
currently available models can completely reproduce the complex environment of a human 
tumor and thus completely recapitulate the disease (Anisimov et al., 2005).  
Commonly used mouse models of breast cancer overexpress Erbb2/neu (Guy et al., 1992b; 
Muller et al., 1988) or the PyMT (Guy et al., 1992a) oncogenes under the MMTV-LTR 
promoter. The PyMT model develops focal mammary tumors with 100 % penetrance, short 
latency and resemble, to some extent, the biological markers and stages seen in the progression 
of human breast cancer (Lin et al., 2003). Males also develop mammary tumors albeit with a 
longer latency (Guy et al., 1992a). The PyMT model was chosen in Paper III to study the 
effects of PAK4 abrogation in mammary tumorigenesis because PAK4 was found 
overexpressed in PyMT-driven tumors.  
It is well established that different genetic murine backgrounds have an impact on the resulting 
PyMT-driven phenotype (Davie et al., 2007). The original PyMT model in the FVB/N 
background (Guy 1992) is often used because of the short tumor latency it exhibits and the very 
high incidence of metastasis in the lung. However, the PyMT model obtained after continued 
backcrossing into the C57Bl/6J strain has a much longer latency. This strain seems to be less 
susceptible and more resistant to PyMT-driven mammary tumorigenesis (Davie et al., 2007). 
The PAK4 conditional knockout model developed in Paper I had been backcrossed to the 
C57Bl/6J strain and, as such, the PyMT model chosen in Paper III matched the strain 
background of the PAK4 conditional knockout mouse. Conversely, the FVB/strain was the 
choice to create in Paper III the MMTV-PAK4 mice, to enhance the possibility of detecting 
mammary tumors.  
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4 RESULTS AND DISCUSSION 
Constitutive PAK4 depletion in mice results in embryonic lethality by day E11.5 due to heart 
defects (Qu et al., 2003). PAK4-null mice also showed neuronal defects and abnormal 
vascularization (Qu et al., 2003). Therefore, models of conditional PAK4 knockout in various 
tissues have since been developed (Nekrasova and Minden, 2012; Tian et al., 2009; Tian et al., 
2011).  
In Paper I and Paper II two mouse models with conditional PAK4 depletion in the mammary 
gland and pancreas, respectively, were created and the consequences of PAK4 depletion were 
analyzed.  
In Paper I, PAK4fl/fl mice (Tian et al., 2009) were crossed with MMTV-Cre (line D) (Wagner 
et al., 1997) to target Cre expression to the mammary epithelium and consequently deplete 
PAK4 expression in mammary epithelial cells. The phenotype of the resulting MMTV-
Cre;PAK4fl/fl mice (referred to as PAK4MEp−/−) was then compared to MMTV-Cre mice 
(PAK4MEp+/+) because Cre expression has been show to disrupt physiological processes, 
including lactation (Robinson and Hennighausen, 2011). 
As judged by immunohistochemistry, Cre expression was readily detected in over 90% of 
mammary epithelial cells, in agreement with the substantial reduction in PAK4 expression 
observed in both luminal and myoepithelial compartments of the mammary ducts. Even though 
the approach was largely successful, it is important to notice the incomplete penetrance of Cre 
expression and that some (albeit few) mammary epithelial cells retained PAK4 expression. 
This was likely a consequence of the stochastic nature of transgene expression characteristic of 
this model, leading to a previously recognized mosaic pattern of expression (Wagner et al., 
2001; Wagner et al., 1997).  
Mammary glands harvested from PAK4MEp−/− mice largely resembled those of control, 
PAK4MEp+/+, mice with regards to ductal elongation and branching during postnatal mammary 
gland development. Consistently, markers of cell proliferation (Ki67-positivity) and invasion 
(MMPs expression and activity) were detected to a similar extent in both genotypes.  
Importantly, the body weight of the offspring of both PAK4MEp−/− and PAK4MEp+/+ dams was 
identical at weaning, suggesting that PAK4MEp−/− mice were able to efficiently nurse their 
progeny. This observation was also coherent with the identical morphologies of mammary 
tissues harvested on the second day of lactation. 
Altogether, the data suggests that PAK4 is dispensable for the development and function of the 
murine mammary gland. That contrasts with the previously known role of PAK1 whose 
depletion in mammary epithelial cells impairs lobuloalveolar development and cell 
differentiation (Wang et al., 2003). 
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In Paper II, PAK4fl/fl mice (Tian et al., 2009) were crossed with Pdx1-Cre mice (Hingorani et 
al., 2003) to target Cre expression to early pancreatic progenitors and attain PAK4 depletion in 
both exocrine and endocrine pancreatic compartments. Immunoblot analyses of whole 
pancreas lysates revealed the success of this approach given that PAK4 expression was below 
the detection limit in samples harvested from mice with conditional PAK4 knockout.  
Pancreatic tissues harvested from conditional PAK4 knockout mice largely resembled their 
wild-type counterparts. Histomorphological and immunohistochemistry-based analyses of the 
exocrine pancreas revealed the expected distribution of ductal and acinar structures, 
appropriately labeled by anti-cytokeratin 19 and anti-amylase antibodies, respectively. 
Likewise, analyses of the endocrine pancreatic compartment revealed equal numbers of 
randomly scattered islets of Langerhans and no difference was observed in islet size between 
the groups. Additionally, the various cell types were present in the right proportion and 
localization in the islets: insulin-stained β-cells were abundant and formed the core of the islets 
that were delimited in the periphery by glucagon-stained α-cells. 
Importantly, no discernible differences were detected between the two genotypes regarding 
body weight at various ages and mice of both genotypes displayed identical glucose induction 
and clearance curves as assessed with a glucose tolerance test, suggesting that PAK4 depletion 
does not affect the unchallenged glucose regulatory function.  
These results are similar to those obtained with PAK5, PAK6, and double PAK5/PAK6 
knockout mice (Furnari et al., 2013, 2014; Nekrasova et al., 2008) but contrast with the 
previously known roles for PAK1 and PAK3 in pancreatic function. Specifically, 
PAK1 depletion impaired glucose homeostasis with defects observed in the secretion of 
insulin and atypical clearance of glucose (Wang et al., 2011) and glucose tolerance after high 
fat diet was altered as a result of PAK3 depletion (Piccand et al., 2014).  
Thus, conclusions of Paper I and Paper II support the idea that different PAK family members 
fulfill distinct functions throughout organ development (Kelly and Chernoff, 2012). 
Furthermore, the lack of overt phenotypes in these new conditional mouse models with PAK4 
depletion offered the exciting possibility of using these models to study the role of PAK4 in 
disease settings. Given the common frequency of breast cancer diagnoses and associated 
lethality (Bray et al., 2018), the role of PAK4 in breast cancer was explored in Paper III. 
A potential role for PAK4 in breast cancer has been suggested in the literature (Rane and 
Minden, 2019) but, until now, the hypothesis remained untested in vivo. To address it, a mouse 
model with PAK4 overexpression in the mammary epithelium was established using the 
MMTV-LTR promoter in an inbred FVB/N strain. Mammary glands of virgin MMTV-PAK4 
mice were phenotypically indistinguishable from their wild-type counterparts until the age of 
6 months, when signs of hyperplasia and mammary lesions became apparent. By the age of 
20–24 months (approximately equivalent to 56–69 years old humans (Flurkey et al., 2007)), 
25 % of MMTV-PAK4 mice developed palpable mammary tumors while all age-matched 
wild-type FVB/N females remained tumor-free. It is important to highlight that the incidence 
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of mammary tumors upon PAK4 overexpression was analyzed in cohorts of virgin, nulliparous 
females, thus contrasting with studies where tumor incidence is analyzed after multiple 
pregnancy and lactation cycles to maximize MMTV-driven transgene overexpression that 
peaks during lactation under hormonal influence (Taneja et al., 2009). The relatively low 
penetrance and long latency of tumors developed in mice overexpressing wild-type PAK4 is 
comparable to the phenotype exhibited upon overexpression of a catalytically active PAK1 
mutant that caused mammary tumors in 20% of transgenic females (Wang et al., 2003; Wang 
et al., 2006). Both results suggest that PAK4 and PAK1 act as relatively weak mammary 
oncogenes and are likely facilitators of tumorigenesis driven by other oncogenes. This 
hypothesis was corroborated by the occasional G12C and G13D activating RAS mutations 
detected by whole exome sequencing in mammary tumors harvested from MMTV-PAK4 mice 
and is in line with inhibited tumorigenesis in a KRAS-driven transgenic mouse with PAK1 
deletion (Chow et al., 2012). Given the high prevalence of oncogenic RAS mutations in 
approximately 30% of all human cancers and in over 90% of pancreatic cancers (Prior et al., 
2012) and the limited success in pharmacologically targeting mutant RAS (O'Bryan, 2019), 
PAKs may be attractive therapeutic targets for RAS-driven tumors.  
The PyMT transgenic breast cancer mouse model (Guy et al., 1992a) overexpressed PAK4 and 
thus emerged as a suitable system to study PAK4 depletion in mammary tumorigenesis. The 
PyMT model does not harbor PAK4 amplification (Rennhack et al., 2017) but the oncoprotein 
binds to and co-opts several oncogenic signaling pathways including the RAS and PI3 kinase 
pathways, which are thus candidates for causing PAK4 overexpression in this model (Lin et 
al., 2003). To that end, the mouse model with conditional PAK4 depletion in the mammary 
epithelium created in Paper I, was crossed with MMTV–PyMT mice to generate cohorts of 
MMTV–PyMT;MMTV-Cre;PAK4fl/fl (PyMT;PAK4MEp−/−) and MMTV–PyMT;MMTV-Cre 
(PyMT;PAK4MEp+/+) control mice. By 12 weeks of age, PyMT;PAK4MEp−/− females exhibited 
significantly less lesions and hyperplasia than the control cohort. Consequently, mammary 
tumors were first palpable considerably later in PyMT;PAK4MEp−/− females which, in turn, 
matched their extended overall survival. 
Interestingly, male mice also develop PyMT-driven mammary tumors that exhibit a slower 
kinetics of tumor initiation and progression compared to the accelerated female model (Guy et 
al., 1992a). Importantly, the differences in tumor latency prompted by PAK4 abrogation were 
even better discerned in this male model, further supporting the important impact of PAK4 in 
mammary tumorigenesis. While breast cancer is common in females and is universally studied 
in females, male breast cancer is a rare disease. Male breast cancer in human usually presents 
at later and more advanced stages and, as a consequence, survival rates are lower for men and 
have not improved over the recent years as female outcomes have (Anderson et al., 2010). 
Thus, there is an obvious importance of also studying male breast cancer. 
At this stage, it was important to recognize the complexity and the caveats inherent to the model 
system used and to evaluate how the experimental outcome may have been affected. PyMT-
driven tumors could develop in all ten murine mammary glands simultaneously; often multiple 
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tumors arose per gland, until eventually, a faster/dominant tumor reached the humane endpoint 
determined by the ethical application (and that was used as a proxy for overall survival). 
Adding to this already heterogeneous model, MMTV-driven Cre expression often results in a 
mosaic pattern of target gene depletion as previously identified in Paper I and in the literature 
(Pylayeva et al., 2009; Wagner et al., 1997). Furthermore, given that Cre and PyMT expression 
is not directed to the exact same cells, stochastically, some cells could co-express Cre and 
PyMT while other cells could express only Cre, PyMT or none of the transgenes. Given the 
strong nature of the PyMT oncogene, cells with PyMT expression would very likely be the 
only cells that contribute to tumors. To grasp the extent of Cre-mediated recombination and the 
efficiency of PAK4 depletion, PAK4 and Cre expression was analyzed in the dominant tumors 
of both cohorts at the humane experimental endpoint. Immunoblot analyses of whole tumor 
extracts and immunostaining of tumor sections with an anti-PAK4 antibody (only suitable to 
detect high PAK4 expression) revealed substantial, although incomplete, PAK4 depletion in 
tumors harvested from the PyMT;PAK4MEp-/- group. Additionally, to evaluate the spatial 
distribution of the remaining PAK4 expression and the discernment of hypothetical discrete 
subpopulations of tumor cells with differential PAK4 expression, in situ hybridization 
(RNAScope) and a semi-quantitative scoring system to detect low and high PAK4 mRNA 
levels in murine mammary tissues was set-up. Results of in situ hybridization revealed that 
PAK4 expression was lower in early lesions but readily detected in late-stage control tumors 
(PyMT;PAK4MEp+/+) that also presented small cell sub-populations with undetectable PAK4 
(such cells are likely unaffected by Cre-mediated PAK4 depletion and may have contributed 
to the tumors that arose in PyMT;PAK4MEp-/- mice). Importantly, in situ hybridization analyses 
revealed substantial PAK4 expression remaining in tumor areas of PyMT;PAK4MEp-/- 
mammary tissues, indicating that PAK4 depletion was incomplete and suggesting that 
remaining PAK4 may have contributed to tumors. Thus, the effect of PAK4 ablation in 
mammary tumorigenesis was likely underscored in this model system. Consistently, a mosaic 
pattern of Cre expression was identified that was particularly obvious in mammary tumors 
derived from PyMT;PAK4MEp-/- mice where Cre expression was substantially lower.  
The prominent effect of PAK4 abrogation in reducing hyperplasia and lesions in 12 weeks old 
mammary glands and the selectivity against Cre-positive (thus PAK4 depleted) cells in late-
stage tumors suggested that PAK4 potentially acts at an early stage of tumorigenesis, when 
senescence (specifically OIS) acts as a recognized barrier to early tumor development (Collado 
et al., 2005; Narita and Lowe, 2005). Given that tumors harvested from MMTV-PAK4 mice 
often displayed oncogenic RAS mutations, the hypothesis that PAK4 may facilitate RAS-
driven cancers by overcoming the senescence barrier was tested using an established model 
where human mammary epithelial cells harbor inducible H-RAS-V12 and display a typical 
OIS growth arrest upon 4-OHT treatment (Borgdorff et al., 2010). Indeed, upon PAK4 
overexpression, H-RAS-V12-induced HMECs retained some proliferative capacity, 
suggesting that PAK4 overexpression confers a selective advantage to cells and offering an 
explanation for the high PAK4 expression levels often seen in cancer. Conversely, a 
senescence-like response (characterized by growth arrest accompanied by additional 
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senescence-associated features such as a flat and enlarged cellular morphology, increased SA-
β-gal activity, and senescence-associated gene expression changes) was restored in a large 
panel of cancer cells subjected to siRNA-, shRNA- or CRISPR/Cas9-mediated PAK4 
inhibition in vitro. Importantly, evidence of a senescence-like response upon PAK4 inhibition 
was observed in three in vivo settings. First, SA-β-gal activity was compared in mammary 
tissues harvested from 8–11 weeks old PyMT;PAK4MEp-/- and PyMT;PAK4MEp+/+ mice. 
Although technically challenging (due to the inherent heterogeneity of the model discussed 
above and given the high abundance of senescence at this stage, as it is known for other cancers 
(Collado et al., 2005), a modest increase in SA-β-gal activity was found in mammary lesions 
of PyMT;PAK4MEp-/- mice, as compared to control. Then, PyMT-driven tumors treated with a 
PAK4 inhibitor (PF-03758309) that was previously shown to block the growth of several tumor 
xenografts (Murray et al., 2010) also exhibited increased in SA-β-gal activity. Finally, 
shPAK4-expressing MCF7 breast cancer cells xenografted onto the back of immunodeficient 
mice resulted in smaller tumors that were also highly positive for SA-β-gal activity as compared 
to shControl-expressing tumors. These observations suggest that epithelial cancers of various 
origins, as gliobastomas (Cosset et al., 2017; Franovic et al., 2015), require PAK4 to avoid 
senescence, an idea that is also consistent with the generalized view of PAK4 addiction in 
cancer (Radu et al., 2014). 
Transcriptome analyses by RNA-Sequencing of Hs578T and BT-549 breast cancer cell lines, 
72 hours after siControl- or siPAK4-transfection, revealed a large number of differentially 
expressed NF-κB family members (namely NFKB1, NFKB2 and RELB) and NF-κB response 
genes that was consistent with the known role of NF-κB (canonical NF-κB signaling via 
RELA) in senescent phenotypes (Chien et al., 2011; Vaughan and Jat, 2011). Interestingly, 
RELB, a noncanonical NF-κB subunit whose role in senescence has remained largely unknown 
(Iannetti et al., 2014), was upregulated at mRNA and protein level upon PAK4 knockdown 
and, it was functionally required for growth arrest upon PAK4 depletion in Hs578T breast 
cancer cells. Furthermore, both endogenous and overexpressed PAK4 and RELB could be 
reciprocally co-immunoprecipitated from cancer cell extracts, which suggested their 
interaction in living cells. Additionally, radioactive kinase assays and mass spectrometry-
guided mapping identified PAK4 as a RELB kinase that phosphorylates the residue serine 151 
(RELB-Ser151). Importantly, expression of phospho-mimicking RELB-S151E (Serine → 
Glutamic Acid substitution) did not affect Hs578T cell proliferation while wild-type RELB 
expression readily reduced it, thus consistent with the results presented above. RELB-Ser151 
is evolutionarily conserved among species, sits in the DNA-binding RHD of RELB and is 
directly bound to the DNA backbone via a hydrogen bond as observed in the crystal structure 
of the complex RELB-DNA (PDB ID: 3DO7) (Fusco et al., 2009). Our computational 
modeling of the potential effect of Ser151 phosphorylation predicted a weakened binding of 
RELB to DNA that was validated in an ELISA-based comparison of phospho-mimicking 
RELB-S151E (Serine → Glutamic Acid substitution), which exhibited defective binding to 
cognate κb sites, as compared to phospho-null RELB-Ser151A (Serine → Alanine substitution) 
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and to wild-type RELB. In agreement, overexpression of PAK4 in breast cancer cells also 
inhibited the binding of RELB to DNA while the knockdown of PAK4 increased it. 
Given the important role of post-translational modifications in regulating the transcriptional 
activity of NF-κB subunits (Baud and Collares, 2016), we further explored consequences of 
RELB-Ser151 phosphorylation by comparing RELB-S151E to wild-type RELB in a qPCR 
array designed to include senescence-associated genes that were differentially expressed upon 
PAK4 knockdown in breast cancer cells as determined by RNA-Sequencing. C/EBPβ, whose 
role in senescence has been previously demonstrated (Hoare et al., 2016), emerged as the top 
altered hit. Importantly, C/EBPβ is upregulated upon PAK4 knockdown and co-knockdown of 
C/EBPβ and PAK4 partially rescued the proliferative arrest induced by PAK4 depletion. Given 
the recognized roles and feedback loops of NF-κB, C/EBPβ and NOTCH1 signaling (Hoare et 
al., 2016), it remains to be elucidated if and how these effects are mediated by the SASP and 
PAK4. Nevertheless, this data added RELB-Ser151 to the short list of known RELB 
phosphorylation sites (Baud and Collares, 2016) and presented RELB-Ser151 as a site that 
bears important consequences for tuning RELB transcriptional activity, target gene expression 
and consequently, for the regulation of cancer cell proliferation.  
Importantly, the in vitro and in vivo findings presented in Paper III were largely supported by 
correlations in patient-derived clinical datasets, in particular the large METABRIC breast 
cancer cohort that includes RNA, DNA and clinical data for approximately 2000 breast cancer 
patients (Curtis et al., 2012). PAK4 overexpression was found in breast tumors as compared to 
normal breast tissues in the METABRIC dataset and validated in two independent datasets of 
breast cancer (TCGA, 2012; Zhao et al., 2004). Noticeably, PAK4 overexpression was found 
across all breast cancer subtypes regardless if stratified according to the PAM50 signature 
(Parker et al., 2009) or the IC10 integrative clusters (Curtis et al., 2012). PAK4 overexpression 
was associated with poor patient prognosis, specifically shorter disease-specific survival and 
overall survival. Furthermore, we also found that only approximately 2 % of breast cancer 
patients carried tumors harboring PAK4 amplification that was nevertheless clinically relevant 
given that these patients tended to exhibit worse clinical outcome. This is in agreement with 
the previous notion that PAKs overexpression in breast cancer is likely due to mRNA 
upregulation (Kumar and Li, 2016). On the mechanistic side, a positive correlation between 
PAK4 expression and the proliferative score of tumors was observed while PAK4 expression 
was negatively correlated with an NFKB signature and RELB expression specifically in breast 
tumors but not in normal breast. Also, the HER2-positive breast cancer patients exhibiting 
PAK4low/RELBhigh expression exhibited a better prognosis. Interestingly, this breast cancer 
subtype shows the highest PAK4 expression and we also detected a positive correlation 
between HER2 signaling and PAK4 expression in the same dataset.  
Finally, patient-derived breast cancer cells were susceptible to growth arrest upon PAK4 
knockdown ex vivo while primary, non-immortalized, HMECs did not show signs of growth 
arrest despite further reduction of their low PAK4 levels. This substantiates the concept that 
PAK4-addicted cancer cells may be selectively targeted. 
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5 CONCLUSIONS 
 
This thesis contributed novel PAK4 mouse models that invite the study of the role of PAK4 in 
the physiology and diseases afflicting the mammary gland and the pancreas in vivo. 
Additionally, this thesis comprehensively addressed the role of PAK4 in breast cancer and 
uncovered a novel function and mechanism by which PAK4 expression in oncogene-activated 
cells overcomes the senescence barrier and promotes mammary tumorigenesis. Importantly, 
this selective advantage conferred by PAK4 in early stages of tumorigenesis then becomes a 
selective vulnerability (an “Achilles heel”) of established cancers, where a senescence-like 
response can be restored upon PAK4 inhibition, via a mechanistic axis linking PAK4 to the 
noncanonical NF-κB signaling subunit RELB and C/EBPβ. This work thus offers an additional 
reason for the frequent PAK4 overexpression in cancer and provides further incentive to the 
assessment of PAK4 as therapeutic strategy in cancer settings. 
 
 
Figure 7 | Schematic summary models for the novel role of PAK4 in breast cancer.                                                          .  
(A) Normal, non-immortalized, human mammary epithelial cells (that express low PAK4 levels, grey cells) 
normally undergo senescence imposed by oncogenic mutations (OIS, blue cells). In a context of PAK4 
overexpression, oncogene-activated cells are able to overcome the OIS barrier and selectively contribute to tumor 
masses (hence the high PAK4 expression often found in tumors, purple cells). These tumor cells are addicted to 
PAK4 expression and PAK4 inhibition leads to a restored senescence–like phenotype, a selective vulnerability 
that may be clinically exploited for cancer therapy.                                                                                                                                        .  
(B) Mechanistically, PAK4 directly interacts with RELB and phosphorylates RELB–Ser151. In a context of PAK4 
abundance (i.e. cancer, purple cells), this impairs the binding of RELB to DNA and the transcription of senescence 
regulators including C/EBPβ, resulting in cancer cell proliferation. Upon PAK4 inhibition, RELB accumulates, 
which culminates in the expression of C/EBPβ and the induction of a senescence-like growth arrest (blue cells).  
Panel A: Inspired by Narita and Lowe, 2005                                                                                                                                                                                                  . 
Panel B: From Costa et al., 2019. 
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6 FUTURE PERSPECTIVES 
 
The coming years will likely warrant a better understanding of fundamental aspects of cancer 
biology and its core cellular and molecular mechanisms. Additionally, evolving technologies 
will contribute to our understanding of cancer beyond what we can currently grasp.  
Zooming in on the PAKs, nearly twenty-five years have passed from the time when they were 
first cloned to the current understanding of PAKs as clinically relevant signaling hubs affecting 
many of the hallmarks of cancer. The substantial evidence that has been gathered by others and 
in this thesis strongly supports the PAK family members (and specifically PAK4) as suitable 
targets for cancer therapy. It is therefore anticipated that the scientific community will continue 
to devote attention to PAK4 and the other PAK family members to better grasp how they signal 
and function in cancer versus normal cells; how their activity is regulated by auto-regulatory 
mechanisms, intracellular and extracellular cues; their list of known substrates and upstream 
regulators is likely to increase and unknown feedback loops will likely be exposed. Moreover, 
there is still a lot to uncover regarding the overlapping and distinct roles for the various PAKs 
in health and disease and a better understanding of the co-dependence and co-expression of 
PAKs will likely come about. From a clinical perspective, the usefulness of isoform-specific 
PAK inhibitors and even PAN-PAK inhibitors as therapeutic targets remains to be ascertained. 
We will soon learn the outcome of an ongoing clinical trial and additional trials will probably 
be announced given the ongoing efforts towards the development of better PAK(4) inhibitors.  
It is my conviction that empowered with a better understanding of basic biology, we will be 
better able to clinically tackle cancer and reduce its mortality, a hope that is shared by the World 
Health Organization and by all of us who have, have had or personally know or have known 
someone with cancer.  
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